Login to Your Account



Valeant Gets $125M Up Front from GSK in Epilepsy Deal

By Catherine Hollingsworth


Friday, August 29, 2008
Valeant Pharmaceuticals International and GlaxoSmithKline plc said they are collaborating on the investigational drug retigabine for epilepsy, a deal that gives Valeant a $125 million up-front payment. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription